Surf early to higher tides : surfactant therapy to optimize tidal volume, lung recruitment, and iNO response

Inhaled nitric oxide is approved by FDA for the management of hypoxemic respiratory failure in term and near-term infants. However, approximately a third of patients treated with inhaled nitric oxide fail to have a sustained improvement in oxygenation. Recruitment of the lung with surfactant enables optimal delivery of nitric oxide to the alveolar space leading to effective pulmonary vasodilation.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:41

Enthalten in:

Journal of perinatology : official journal of the California Perinatal Association - 41(2021), 1 vom: 13. Jan., Seite 1-3

Sprache:

Englisch

Beteiligte Personen:

Konduri, Girija G [VerfasserIn]
Lakshminrusimha, Satyan [VerfasserIn]

Links:

Volltext

Themen:

31C4KY9ESH
Editorial
Nitric Oxide
Pulmonary Surfactants
Surface-Active Agents

Anmerkungen:

Date Completed 31.08.2021

Date Revised 02.01.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1038/s41372-020-0764-4

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313673063